US Patent

US8980931 — Method of evaluating pharmaceutical preparation containing luliconazole and index substance

Formulation · Assigned to Pola Pharma Inc · Expires 2034-04-28 · 8y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a method for evaluating the stability of a pharmaceutical preparation containing luliconazole.

USPTO Abstract

Disclosed is a method of evaluating stability of a pharmaceutical preparation containing luliconazole. The method includes measuring an amount of production of an SE form of luliconazole represented by following formula (2), an amount of production of a Z form of luliconazole represented by following formula (3) and an amount of production of an amide form of luliconazole represented by following formula (1) after storage under a severe condition or an accelerated condition, and judging that the stability of the pharmaceutical preparation is high if each of the amount of production of the SE form, the amount of production of the Z form and the amount of production of the amide form is not more than 5% by weight with respect to a compounded amount of luliconazole.

Drugs covered by this patent

Patent Metadata

Patent number
US8980931
Jurisdiction
US
Classification
Formulation
Expires
2034-04-28
Drug substance claim
No
Drug product claim
Yes
Assignee
Pola Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.